Showing results (31-40 of 43) with videos related to
Sort By:
Pageof 5
JTCVS Open|February 23, 2022
Effect of COVID-19 on the delivery of care for thoracic surgical patientsDao M Nguyen, Karishma Kodia, Joanne Szewczyk, et al.JTCVS Open|January 11, 2024
Postoperative day 1 discharge following robotic thoracoscopic pulmonary anatomic resections in the era of enhanced recovery protocol: A single-institution experienceDaniel J Gross, Ahmed Alnajar, Luis Miguel Cotamo, et al.The Annals of Thoracic Surgery|January 30, 2024
Neoadjuvant vs Adjuvant Chemoimmunotherapy for Stage II-IIIB Non-Small Cell Lung CancerRussell Seth Martins, Syed Shahzad Razi, Ahmed Alnajar, et al.Annals of Thoracic Surgery Short Reports|January 10, 2025
Social Determinants of Health Impact on Survival of Patients With Malignant Pleural MesotheliomaAhmed Alnajar, Samuel A Kareff, Syed S Razi, et al.Innovations (Philadelphia, Pa.)|December 3, 2020
Current Surgical Risk Scores Overestimate Risk in Minimally Invasive Aortic Valve ReplacementAhmed Alnajar, Subhasis Chatterjee, Brendan P Chou, et al.JTCVS Open|February 29, 2024
Outcomes of minimally invasive isolated tricuspid valve repair and replacement through right mini-thoracotomyAhmed Alnajar, Subhasis Chatterjee, Jacqueline K Olive, et al.JAMA Network Open|March 23, 2023
Disparities in Survival Due to Social Determinants of Health and Access to Treatment in US Patients With Operable Malignant Pleural MesotheliomaAhmed Alnajar, Samuel A Kareff, Syed S Razi, et al.Journal of Thoracic Disease|July 10, 2023
Twenty-year survival following lung transplantationJohn James Miggins, Ross M Reul, Spencer Barrett, et al.Journal of Clinical Medicine|February 13, 2025
Outcomes of Resectable Locally Advanced Non-Small Cell Lung Cancer After Neoadjuvant Chemoimmunotherapy: A Single Institution ExperienceJose Noy, Alexander Chang, Nelly P Chow, et al.Journal of Cardiac Surgery|September 4, 2019
Device exchange from Heartmate II to HeartWare HVADRachel A Beaupre, Ahmed Alnajar, Tadahisa Sugiura, et al.Pageof 5